Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Folinic Acid as a Treatment for Autism Spectrum Disorder in Children
NCT07630506Phase 2Recruiting
- Sponsor
- KK Women's and Children's Hospital
- Start
- May 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autism Spectrum Disorder (ASD) comparing Folinic Acid with Placebo (2 arms). Primary endpoint: Pervasive Developmental Disorder-Behavior Inventory Autism Composite T-Score at 12 weeks. Started May 2025; status: recruiting.
02
Drugs
folinic acid
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT07630506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07630506.